Esthesioneuroblastoma (Olfactory Neuroblastoma) Treated With 111In-Octreotide and 177Lu-DOTATATE PRRT

ABSTRACTA 51-year-old man with a recurrent metastatic esthesioneuroblastoma (olfactory neuroblastoma) was referred for peptide receptor radionuclide therapy (PRRT). He received 4 treatments of In-octreotide over 8 months and 3 treatments of Lu-DOTATATE over 4 months, which helped alleviate his sympt...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical nuclear medicine 2015-04, Vol.40 (4), p.317-321
Hauptverfasser:	Makis, William, McCann, Karey, McEwan, Alexander J.B
Format:	Artikel
Sprache:	eng
Schlagworte:	Esthesioneuroblastoma, Olfactory - radiotherapy Humans Male Middle Aged Nasal Cavity - pathology Nose Neoplasms - radiotherapy Octreotide - analogs & derivatives Octreotide - therapeutic use Organometallic Compounds - therapeutic use Radiopharmaceuticals - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	ABSTRACTA 51-year-old man with a recurrent metastatic esthesioneuroblastoma (olfactory neuroblastoma) was referred for peptide receptor radionuclide therapy (PRRT). He received 4 treatments of In-octreotide over 8 months and 3 treatments of Lu-DOTATATE over 4 months, which helped alleviate his symptoms and improved his quality of life; however, the tumor ultimately progressed and he passed away shortly thereafter. PRRT with In-octreotide or Lu-DOTATATE could play a role in the management of esthesioneuroblastoma.
ISSN:	0363-9762 1536-0229
DOI:	10.1097/RLU.0000000000000705